Table 1 Demographic and clinical characteristics of the OS and PFS cohorts.
Variable | OS cohort (n = 7868) | PFS cohort (n = 6303) |
|---|---|---|
Age on index date, years, mean ± SD | 69.6 ± 9.4 | 69.6 ± 9.5 |
Sex, n (%) | ||
Female | 3371 (42.8) | 2736 (43.4) |
Male | 4496 (57.1) | 3567 (56.6) |
Race, n (%) | ||
Asian | 117 (1.5) | 92 (1.5) |
Black or African American | 703 (8.9) | 568 (9.0) |
Other | 731 (9.3) | 584 (9.3) |
White | 5514 (70.1) | 4402 (69.8) |
Unknown | 803 (10.2) | 657 (10.4) |
Ethnicity, n (%) | ||
Hispanic or Latino | 239 (3.0) | 194 (3.1) |
Non-Hispanic | 7629 (97.0) | 6109 (96.0) |
Practice type, n (%) | ||
Academic | 551 (7.0) | 476 (7.6) |
Community | 7317 (93.0) | 5827 (92.4) |
Payer, n (%) | ||
Commercial | 4279 (54.4) | 3460 (54.9) |
Medicare | 1693 (21.5) | 1348 (21.4) |
Medicaid | 129 (1.6) | 107 (1.7) |
Other/unknown | 1767 (22.5) | 1388 (22.0) |
Region, n (%) | ||
Midwest | 1085 (13.8) | 854 (13.5) |
Northeast | 1504 (19.1) | 1183 (18.8) |
South | 3505 (44.5) | 2831 (44.9) |
West | 1090 (13.9) | 860 (13.6) |
Unknown | 684 (8.7) | 575 (9.1) |
ECOG performance status before or on the index date, n (%) | ||
0 | 1829 (23.2) | 1476 (23.4) |
1 | 2806 (35.7) | 2241 (35.6) |
2 | 1140 (14.5) | 907 (14.4) |
3 | 246 (3.1) | 191 (3.0) |
4 | 13 (0.2) | 11 (0.2) |
Missing | 1834 (23.3) | 1477 (23.4) |
Histology, n (%) | ||
NSCLC histology NOS | 367 (4.7) | 288 (4.6) |
Non-squamous cell carcinoma | 5155 (65.5) | 4310 (68.4) |
Squamous cell carcinoma | 2346 (29.8) | 1705 (27.1) |
Smoking status, n (%) | ||
History of smoking | 7225 (91.8) | 5792 (91.9) |
No history of smoking | 638 (8.1) | 507 (8.0) |
Unknown/not documented | 5 (0.1) | 4 (0.1) |
Stage at initial diagnosis, n (%) | ||
Stage 0/I | 573 (7.3) | 459 (7.3) |
Stage II | 467 (5.9) | 298 (4.7) |
Stage IIIA | 1071 (13.6) | 631 (10.0) |
Stage IIIB/C | 281 (3.6) | 231 (3.7) |
Stage IV | 5264 (66.9) | 4546 (72.1) |
Unknown | 212 (2.7) | 138 (2.2) |
Year of initial NSCLC diagnosis | 2017.8 (1.9) | 2018.1 (1.7) |
Year of advanced NSCLC diagnosis | 2018.3 (1.3) | 2018.5 (1.2) |
Systemic treatment, n (%) | ||
ICI only | 2685 (34.1) | 2685 (42.6) |
ICI and chemotherapy | 4328 (55.0) | 3592 (57.0) |
ICI and other | 855 (10.9) | 26 (0.4) |
Outcome | ||
Follow-up days, mean ± SD | 350.5 ± 346.4 | 260.3 ± 297.4 |
Observed events, n (%) | 4879 (62.0) | 5073 (80.5) |
